2025年前三季度,A股医药行业在转型阵痛中勾勒出清晰的复苏轮廓。整体营收17480.2亿元、归母净利润1355.8亿元的微降数据,与创新药板块21.41%的营收高增形成鲜明反差,而第三季度收入利润双双转正的表现,更成为行业筑底回升的关键佐证。在医保控费深化与创新转型提速的双重背景下,医药行业正告别同质化竞争的旧周期,步入“整体企稳、结构突围”的新发展阶段。从行业全局视角观察,前三季度的微降态势...
Source Link2025年前三季度,A股医药行业在转型阵痛中勾勒出清晰的复苏轮廓。整体营收17480.2亿元、归母净利润1355.8亿元的微降数据,与创新药板块21.41%的营收高增形成鲜明反差,而第三季度收入利润双双转正的表现,更成为行业筑底回升的关键佐证。在医保控费深化与创新转型提速的双重背景下,医药行业正告别同质化竞争的旧周期,步入“整体企稳、结构突围”的新发展阶段。从行业全局视角观察,前三季度的微降态势...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.